The National Institutes of Health intends to issue a firm-fixed-price purchase order to Ingenious Targeting Laboratory Inc. for a custom inducible knockin mouse, based on a determination that this is the only responsible source able to meet the requirement. The specific need is for an endogenous Gcm2 genomic modification, which cannot be satisfied by generic CRISPR/Cas9 mouse generation or by transgene expression using a heterologous promoter. This notice is not a request for competitive quotes, but eligible small businesses may submit a written capability statement demonstrating their ability to perform the requirement. The Government